Medicare patients face high costs for newer injected cholesterol drugs

(Reuters Health) – Newer injected cholesterol medicines known as PCSK9 inhibitors can cost Medicare patients more than US$300 a month, compared with only about US$4 for older statin pills to lower cholesterol, a U.S. study suggests.

Nationwide, approximately 9 million adults with heart disease and …
Go to Source